Shuangcheng Pharmaceutical: Announcement of Hainan Shuangcheng Pharmaceutical Co., Ltd. on the progress of major asset restructuring
Shuangcheng Pharmaceutical: Instructions of the board of directors of Hainan Shuangcheng Pharmaceutical Co., Ltd. that the transaction complies with the provisions of Articles 11 and 43 of the “Administrative Measures on Major Asset Reorganization of Listed Companies”
Shuangcheng Pharmaceutical: Explanation of the board of directors of Hainan Shuangcheng Pharmaceutical Co., Ltd. on the purchase and sale of assets within 12 months prior to the transaction
Shuangcheng Pharmaceutical: Explanation of the board of directors that there are no entities involved in this transaction that are prohibited from participating in the material assets restructuring situation of any listed company as stipulated in Article 12 of the “Supervisory Guidelines for Listed Companies No. 7 - Supervision of Abnormal Stock Transactions Related to Major Asset Restructurings of Listed Companies” and Article 30 of the “Shenzhen Stock Exchange Listed Companies Self-Regulatory Guidelines No. 8 - Major Asset Restructurings”
Shuangcheng Pharmaceutical: Explanation of the board of directors of Hainan Shuangcheng Pharmaceutical Co., Ltd. on the fluctuation in the company\'s stock price before the transaction information was released
Shuangcheng Pharmaceutical: Explanation of the board of directors of Hainan Shuangcheng Pharmaceutical Co., Ltd. on the completeness and compliance of legal procedures and the effectiveness of submitting legal documents in this transaction
Shuangcheng Pharmaceutical: Instructions of the board of directors of Hainan Shuangcheng Pharmaceutical Co., Ltd. that the transaction complies with the provisions of Article 11 of the “Administrative Measures on Securities Issuance and Registration of Listed Companies”
Shuangcheng Pharmaceutical: Explanation of the board of directors of Hainan Shuangcheng Pharmaceutical Co., Ltd. on whether this transaction constituted a major asset restructuring, related transaction and restructuring listing
Shuangcheng Pharmaceutical: Instructions of the board of directors of Hainan Shuangcheng Pharmaceutical Co., Ltd. that the transaction complies with the provisions of Article 4 of the “Guidelines for the Supervision of Listed Companies No. 9 - Regulatory Requirements for Listed Companies to Plan and Implement Major Asset Restructurings”
Shuangcheng Pharmaceutical: Explanation of the board of directors of Hainan Shuangcheng Pharmaceutical Co., Ltd. on the confidentiality measures and confidentiality system adopted in this transaction
Shuangcheng Pharmaceutical: Announcement on the controlling shareholder's securities financing business
Shuangcheng Pharmaceutical: Announcement on the controlling shareholder's securities financing business
Shuangcheng Pharmaceutical: Announcement on the progress of the company signing the “Product Rights Transfer Agreement”
Shuangcheng Pharmaceutical: Announcement on the company's signing of the “Product Rights Transfer Agreement” and progress
Shuangcheng Pharmaceutical: Announcement on Disposal of Idle Assets
Shuangcheng Pharmaceutical: Progress announcement on the sale of 46% of the shares of the participating company Australasia Biotech
Shuangcheng Pharmaceutical: Progress announcement on the sale of 46% of the shares of the participating company Australasia Biotech
Shuangcheng Pharmaceutical: Progress announcement on the sale of 46% of the shares of the participating company Australasia Biotech
Shuangcheng Pharmaceutical: Announcement on the progress of asset sales and related transactions
Shuangcheng Pharmaceutical: Progress announcement on the sale of 46% of the shares of the participating company Australasia Biotech
No Data
No Data